Consistent with these findings, Lin et al. reported that the addition of pioglitazone could significantly lower the serum RBP4 and HOMA-IR values in T2DM patients who had been treated with metformin and/or sulfonylurea [125]. This evidence concerns the gene RBP4 and type 2 diabetes mellitus.